TherapeuticsMD, Inc. Research and Development Expense
TherapeuticsMD, Inc. (TXMD) reported Research and Development Expense of $1.11 million for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2022-11-14
- TherapeuticsMD, Inc. research and development expense for the quarter ending 2022-09-30 was $1.11M, a 30.72% decline year-over-year.
- TherapeuticsMD, Inc. research and development expense for the quarter ending 2022-06-30 was $1.58M, a 21.43% decline year-over-year.
- TherapeuticsMD, Inc. research and development expense for the quarter ending 2022-03-31 was $1.40M, a 31.71% decline year-over-year.
- TherapeuticsMD, Inc. research and development expense for the quarter ending 2021-12-31 was $1.42M, a 40.69% decline year-over-year.
- TherapeuticsMD, Inc. research and development expense for fiscal 2021 was $7.09M, a 32.07% decline from fiscal 2020.
- TherapeuticsMD, Inc. research and development expense for fiscal 2020 was $10.43M, a 47.29% decline from fiscal 2019.
- TherapeuticsMD, Inc. research and development expense for fiscal 2019 was $19.79M, a 27.50% decline from fiscal 2018.
- TherapeuticsMD, Inc. research and development expense for fiscal 2018 was $27.30M, a 19.36% decline from fiscal 2017.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2022-09-30 | $1.11M 10-Q · filed 2022-11-14 | $2.69M derived: sum of 2 quarters · filed 2022-11-14 | $4.09M 10-Q · filed 2022-11-14 | $5.51M derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2022-06-30 | $1.58M 10-Q · filed 2022-08-15 | $2.98M 10-Q · filed 2022-08-15 | $4.40M derived: sum of 3 quarters · filed 2022-08-15 | $6.00M derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2022-03-31 | $1.40M 10-Q · filed 2022-05-16 | $2.82M derived: sum of 2 quarters · filed 2022-05-16 | $4.42M derived: sum of 3 quarters · filed 2022-11-14 | $6.44M derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-12-31 | $1.42M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | $3.02M derived: sum of 2 quarters · filed 2022-11-14 | $5.04M derived: sum of 3 quarters · filed 2022-11-14 | $7.09M 10-K · filed 2022-03-23 | ||||
| 2021-09-30 | $1.60M 10-Q · filed 2022-11-14 | $3.62M derived: sum of 2 quarters · filed 2022-11-14 | $5.67M 10-Q · filed 2022-11-14 | $8.06M derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-06-30 | $2.01M 10-Q · filed 2022-08-15 | $4.06M 10-Q · filed 2022-08-15 | $6.46M derived: sum of 3 quarters · filed 2022-08-15 | $8.48M derived: sum of 4 quarters · filed 2022-08-15 | ||||
| 2021-03-31 | $2.05M 10-Q · filed 2022-05-16 | $4.44M derived: sum of 2 quarters · filed 2022-05-16 | $6.47M derived: sum of 3 quarters · filed 2022-05-16 | $9.21M derived: sum of 4 quarters · filed 2022-05-16 | ||||
| 2020-12-31 | $2.39M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | $4.42M derived: sum of 2 quarters · filed 2022-03-23 | $7.16M derived: sum of 3 quarters · filed 2022-03-23 | $10.43M 10-K · filed 2022-03-23 | $10.43M 10-K · filed 2021-03-04 | |||
| 2020-09-30 | $2.03M 10-Q · filed 2021-11-12 | $2.03M 10-Q · filed 2020-11-09 | $4.77M derived: sum of 2 quarters · filed 2021-11-12 | $8.04M 10-Q · filed 2021-11-12 | $8.04M 10-Q · filed 2020-11-09 | $12.47M derived: sum of 4 quarters · filed 2022-03-23 | ||
| 2020-06-30 | $2.74M 10-Q · filed 2021-08-04 | $2.74M 10-Q · filed 2020-08-07 | $6.01M 10-Q · filed 2021-08-04 | $6.01M 10-Q · filed 2020-08-07 | $10.44M derived: sum of 3 quarters · filed 2022-03-23 | $14.52M derived: sum of 4 quarters · filed 2022-03-23 | ||
| 2020-03-31 | $3.27M 10-Q · filed 2021-05-06 | $3.27M 10-Q · filed 2020-05-06 | $7.70M derived: sum of 2 quarters · filed 2022-03-23 | $11.78M derived: sum of 3 quarters · filed 2022-03-23 | $16.74M derived: sum of 4 quarters · filed 2022-03-23 | |||
| 2019-12-31 | $4.43M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | $8.51M derived: sum of 2 quarters · filed 2022-03-23 | $13.47M derived: sum of 3 quarters · filed 2022-03-23 | $19.79M 10-K · filed 2022-03-23 | $19.79M 10-K · filed 2020-02-24 | |||
| 2019-09-30 | $4.08M 10-Q · filed 2020-11-09 | $9.04M derived: sum of 2 quarters · filed 2020-11-09 | $15.36M 10-Q · filed 2020-11-09 | $22.11M derived: sum of 4 quarters · filed 2021-03-04 | ||||
| 2019-06-30 | $4.96M 10-Q · filed 2020-08-07 | $11.28M 10-Q · filed 2020-08-07 | $18.04M derived: sum of 3 quarters · filed 2021-03-04 | $24.74M derived: sum of 4 quarters · filed 2021-03-04 | ||||
| 2019-03-31 | $6.32M 10-Q · filed 2020-05-06 | $13.07M derived: sum of 2 quarters · filed 2021-03-04 | $19.78M derived: sum of 3 quarters · filed 2021-03-04 | $26.58M derived: sum of 4 quarters · filed 2021-03-04 | ||||
| 2018-12-31 | $6.75M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $13.46M derived: sum of 2 quarters · filed 2021-03-04 | $20.26M derived: sum of 3 quarters · filed 2021-03-04 | $27.30M 10-K · filed 2021-03-04 | ||||
| 2018-09-30 | $6.71M 10-Q · filed 2019-11-08 | $13.51M derived: sum of 2 quarters · filed 2019-11-08 | $20.55M 10-Q · filed 2019-11-08 | $31.52M derived: sum of 4 quarters · filed 2020-02-24 | ||||
| 2018-06-30 | $6.80M 10-Q · filed 2019-08-09 | $13.84M 10-Q · filed 2019-08-09 | $24.81M derived: sum of 3 quarters · filed 2020-02-24 | $31.25M derived: sum of 4 quarters · filed 2020-02-24 | ||||
| 2018-03-31 | $7.04M 10-Q · filed 2019-05-08 | $18.01M derived: sum of 2 quarters · filed 2020-02-24 | $24.45M derived: sum of 3 quarters · filed 2020-02-24 | $33.17M derived: sum of 4 quarters · filed 2020-02-24 | ||||
| 2017-12-31 | $10.97M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | $17.41M derived: sum of 2 quarters · filed 2020-02-24 | $26.13M derived: sum of 3 quarters · filed 2020-02-24 | $33.85M 10-K · filed 2020-02-24 | ||||
| 2017-09-30 | $6.44M 10-Q · filed 2018-11-08 | $15.15M derived: sum of 2 quarters · filed 2018-11-08 | $22.88M 10-Q · filed 2018-11-08 | $33.22M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2017-06-30 | $8.72M 10-Q · filed 2018-07-30 | $16.44M 10-Q · filed 2018-07-30 | $26.78M derived: sum of 3 quarters · filed 2019-02-27 | $41.45M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2017-03-31 | $7.72M 10-Q · filed 2018-05-07 | $18.07M derived: sum of 2 quarters · filed 2019-02-27 | $32.73M derived: sum of 3 quarters · filed 2019-02-27 | $46.57M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2016-12-31 | $10.34M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $25.01M derived: sum of 2 quarters · filed 2019-02-27 | $38.85M derived: sum of 3 quarters · filed 2019-02-27 | $53.94M 10-K · filed 2019-02-27 | ||||
| 2016-09-30 | $14.66M 10-Q · filed 2017-11-07 | $28.51M derived: sum of 2 quarters · filed 2017-11-07 | $43.60M 10-Q · filed 2017-11-07 | $56.86M derived: sum of 4 quarters · filed 2018-02-23 | ||||
| 2016-06-30 | $13.84M 10-Q · filed 2017-08-03 | $28.94M 10-Q · filed 2017-08-03 | $42.19M derived: sum of 3 quarters · filed 2018-02-23 | $58.61M derived: sum of 4 quarters · filed 2018-02-23 | ||||
| 2016-03-31 | $15.10M 10-Q · filed 2017-05-03 | $28.35M derived: sum of 2 quarters · filed 2018-02-23 | $44.77M derived: sum of 3 quarters · filed 2018-02-23 | $68.96M derived: sum of 4 quarters · filed 2018-02-23 | ||||
| 2015-12-31 | $13.25M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23 | $29.68M derived: sum of 2 quarters · filed 2018-02-23 | $53.87M derived: sum of 3 quarters · filed 2018-02-23 | $72.04M 10-K · filed 2018-02-23 | ||||
| 2015-09-30 | $16.42M 10-Q · filed 2016-11-04 | $40.61M derived: sum of 2 quarters · filed 2016-11-04 | $58.79M 10-Q · filed 2016-11-04 | $72.96M derived: sum of 4 quarters · filed 2017-02-28 | ||||
| 2015-06-30 | $24.19M 10-Q · filed 2016-08-05 | $42.37M 10-Q · filed 2016-08-05 | $56.53M derived: sum of 3 quarters · filed 2017-02-28 | $71.44M derived: sum of 4 quarters · filed 2017-02-28 | ||||
| 2015-03-31 | $18.18M 10-Q · filed 2016-05-05 | $32.34M derived: sum of 2 quarters · filed 2017-02-28 | $47.25M derived: sum of 3 quarters · filed 2017-02-28 | $55.49M derived: sum of 4 quarters · filed 2017-02-28 | ||||
| 2014-12-31 | $14.17M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $29.08M derived: sum of 2 quarters · filed 2017-02-28 | $37.31M derived: sum of 3 quarters · filed 2017-02-28 | $43.22M 10-K · filed 2017-02-28 | ||||
| 2014-09-30 | $14.91M 10-Q · filed 2015-11-05 | $23.14M derived: sum of 2 quarters · filed 2015-11-05 | $29.05M 10-Q · filed 2015-11-05 | $34.89M derived: sum of 4 quarters · filed 2016-02-26 | ||||
| 2014-06-30 | $8.23M 10-Q · filed 2015-08-07 | $14.14M 10-Q · filed 2015-08-07 | $19.98M derived: sum of 3 quarters · filed 2016-02-26 | $24.08M derived: sum of 4 quarters · filed 2016-02-26 | ||||
| 2014-03-31 | $5.91M 10-Q · filed 2015-05-07 | $11.75M derived: sum of 2 quarters · filed 2016-02-26 | $15.85M derived: sum of 3 quarters · filed 2016-02-26 | $17.59M derived: sum of 4 quarters · filed 2016-02-26 | ||||
| 2013-12-31 | $5.84M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | $9.94M derived: sum of 2 quarters · filed 2016-02-26 | $11.69M derived: sum of 3 quarters · filed 2016-02-26 | $13.55M 10-K · filed 2016-02-26 | ||||
| 2013-09-30 | $4.10M 10-Q · filed 2014-11-07 | $5.85M derived: sum of 2 quarters · filed 2014-11-07 | $7.71M 10-Q · filed 2014-11-07 | $8.77M derived: sum of 4 quarters · filed 2015-03-12 | ||||
| 2013-06-30 | $1.75M 10-Q · filed 2014-08-07 | $3.31M 10-Q · filed 2014-08-07 | $4.67M derived: sum of 3 quarters · filed 2015-03-12 | $6.38M derived: sum of 4 quarters · filed 2015-03-12 | ||||
| 2013-03-31 | $1.57M 10-Q · filed 2014-05-07 | $2.93M derived: sum of 2 quarters · filed 2015-03-12 | $4.63M derived: sum of 3 quarters · filed 2015-03-12 | $5.46M derived: sum of 4 quarters · filed 2015-03-12 | ||||
| 2012-12-31 | $1.36M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $3.06M derived: sum of 2 quarters · filed 2015-03-12 | $3.90M derived: sum of 3 quarters · filed 2015-03-12 | $4.49M 10-K · filed 2015-03-12 | ||||
| 2012-09-30 | $1.70M 10-Q · filed 2013-11-05 | $1.33M 10-Q · filed 2012-11-13 | $2.54M derived: sum of 2 quarters · filed 2013-11-05 | $3.13M 10-Q · filed 2013-11-05 | $2.58M 10-Q · filed 2012-11-13 | $2.80M derived: sum of 4 quarters · filed 2014-03-05 | ||
| 2012-06-30 | $833.34K 10-Q · filed 2013-08-07 | $1.25M 10-Q · filed 2013-08-07 | $1.10M derived: sum of 3 quarters · filed 2014-03-05 | $1.19M derived: sum of 4 quarters · filed 2014-03-05 | ||||
| 2012-03-31 | $411.96K 10-Q · filed 2013-05-10 | $263.25K derived: sum of 2 quarters · filed 2014-03-05 | $358.47K derived: sum of 3 quarters · filed 2014-03-05 | $464.49K derived: sum of 4 quarters · filed 2014-03-05 | ||||
| 2011-12-31 | -$148.71K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-05 | -$53.49K derived: sum of 2 quarters · filed 2014-03-05 | $52.53K derived: sum of 3 quarters · filed 2014-03-05 | $107.24K 10-K · filed 2014-03-05 | ||||
| 2011-09-30 | $95.22K 10-Q · filed 2012-11-13 | $201.24K derived: sum of 2 quarters · filed 2012-11-13 | $255.95K 10-Q · filed 2012-11-13 | |||||
| 2011-06-30 | $106.02K 10-Q · filed 2012-08-09 | $160.73K 10-Q · filed 2012-08-09 | ||||||
| 2011-03-31 | $54.71K 10-Q · filed 2012-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |